相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
Maura L. Gillison et al.
ONCOLOGIST (2022)
Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy
Wen-Chi Chou et al.
CANCER CONTROL (2022)
Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups
Derian B. Taylor et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2022)
Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer
Zachary S. Mayo et al.
ANTICANCER RESEARCH (2022)
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Cheryl P. Bruijnen et al.
CANCER (2022)
The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study
Stephanie E. Pearson et al.
JOURNAL OF CANCER SURVIVORSHIP (2022)
Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
Gabriele Fasano et al.
MEDICINA-LITHUANIA (2022)
Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma
Alex J. F. Tampio et al.
ENT-EAR NOSE & THROAT JOURNAL (2021)
Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy
Elisabeth G. Vichaya et al.
BRAIN BEHAVIOR AND IMMUNITY (2021)
Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
Justin T. Moyers et al.
CANCER MEDICINE (2021)
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study
F. Gomes et al.
ESMO OPEN (2021)
Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
Antonio Piras et al.
FRONTIERS IN ONCOLOGY (2021)
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Haruka Uezono et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
N. Colombo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Andrea Botticelli et al.
FRONTIERS IN IMMUNOLOGY (2021)
A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer
Anna Lee et al.
INTERNATIONAL JOURNAL OF PARTICLE THERAPY (2021)
Prevalence of comorbidities in elderly cancer patients
Alfa Wenkstetten-Holub et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2021)
Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience
William J. Archibald et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
Minimal acute toxicity from proton beam therapy for major salivary gland cancer
Michael Chuong et al.
ACTA ONCOLOGICA (2020)
Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Erik Haehl et al.
RADIATION ONCOLOGY (2020)
Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group
Nam P. Nguyen et al.
CANCERS (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients
Nicola Alessandro Iacovelli et al.
FRONTIERS IN ONCOLOGY (2020)
Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases
S. Benhmida et al.
CANCER RADIOTHERAPIE (2020)
Gender Disparities in Epidemiology, Treatment, and Outcome for Head and Neck Cancer in Germany: A Population-Based Long-Term Analysis from 1996 to 2016 of the Thuringian Cancer Registry
Andreas Dittberner et al.
CANCERS (2020)
Immunotherapy in Geriatric Patients With Advanced Cancer
Birol Yildiz et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY (2020)
Cisplatin-induced renal toxicity in elderly people
ZhiYu Duan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review
Doris L. van Abbema et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Prevalence of Comorbidities among Older Head and Neck Cancer Survivors in the United States
Danielle F. Eytan et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2019)
Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer
Morgan R. L. Lichtenstein et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Hematologic Complications of Immune Checkpoint Inhibitors
Elizabeth J. Davis et al.
ONCOLOGIST (2019)
Challenges Facing Radiation Oncologists in The Management of Older Cancer Patients: Consensus of The International Geriatric Radiotherapy Group
Tiberiu Popescu et al.
CANCERS (2019)
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
Silvia Martina Ferrari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Racial disparities in outcome among head and neck cancer patients in the United States: An analysis using SEER-Medicare linked database.
Ikumi Suzuki et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Hearing Impairment, Loneliness, Social Isolation, and Cognitive Function: Longitudinal Analysis Using English Longitudinal Study on Ageing
Asri Maharani et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2019)
Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma
Francesca De Felice et al.
MEDICAL ONCOLOGY (2019)
Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment
Liliya Benchetrit et al.
ORAL ONCOLOGY (2019)
Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer
Etienne Dauzier et al.
ORAL ONCOLOGY (2019)
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
Nabil F. Saba et al.
ORAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison et al.
LANCET (2019)
Sex bias: Is it pervasive in otolaryngology clinical research?
Zainab Farzal et al.
LARYNGOSCOPE (2019)
Renal toxicities associated with pembrolizumab
Hassan Izzedine et al.
CLINICAL KIDNEY JOURNAL (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Prediction of mortality and morbidity in head and neck cancer patients 80 years of age and older undergoing surgery
Heidi E. L'Esperance et al.
LARYNGOSCOPE (2018)
Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium
Emanuele Leoncini et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2018)
The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis
Qiang Su et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Toxicity of Cancer Therapies in Older Patients
Olivia Le Saux et al.
CURRENT ONCOLOGY REPORTS (2018)
Diabetic kidney disease in the elderly: prevalence and clinical correlates
Giuseppina T. Russo et al.
BMC GERIATRICS (2018)
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Rawad Elias et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
Alexandre Arthur Jacinto et al.
BMC CANCER (2018)
MRI-guided radiotherapy for head and neck cancer: initial clinical experience
A. M. Chen et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Current studies of immunotherapy in head and neck cancer
V. Dogan et al.
CLINICAL OTOLARYNGOLOGY (2018)
Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice
Juliette Thariat et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
Teresa Magnes et al.
PLOS ONE (2017)
Hormone factors play a favorable role in female head and neck cancer risk
Dana Hashim et al.
CANCER MEDICINE (2017)
Real-life efficacy of volumetric modulated arc therapy in head and neck squamous cell carcinoma
C. Moncharmont et al.
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES (2017)
The future of image-guided radiotherapy will be MR guided
Julianne M. Pollard et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
The Genetic Landscape of Programmed Death Ligand-1 (PD-L1) Alterations in Head and Neck Cancer
Thomas E. Heineman et al.
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
Stefano Maria Magrini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IMRT/VMAT for malignancies in the head-and-neck region
Michelle L. Brown et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2016)
A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)
Jian Guan et al.
ONCOTARGET (2016)
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer
Lauren M. Hamel et al.
CANCER CONTROL (2016)
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
Matthew Zibelman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis
Caitriona B. O'Neill et al.
CANCER (2015)
Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study
T. Xu et al.
ORAL ONCOLOGY (2015)
Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy
Ciro Franzese et al.
RADIATION ONCOLOGY (2015)
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma
David J. Thomson et al.
ACTA ONCOLOGICA (2015)
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Angela Callejo et al.
TOXICS (2015)
Comparison of daily versus nondaily image-guided radiotherapy protocols for patients treated with intensity-modulated radiotherapy for head and neck cancer
Yao Yu et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Health Economic Controversy and Cost-Effectiveness of Proton Therapy
Yolande Lievens et al.
SEMINARS IN RADIATION ONCOLOGY (2013)
Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer
Nam P. Nguyen et al.
BMC CANCER (2012)
Effectiveness of intensity-modulated and image-guided radiotherapy to spare the mandible from excessive radiation
Nam P. Nguyen et al.
ORAL ONCOLOGY (2012)
Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer
N. P. Nguyen et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2012)
Clinical Performance of Automated IMRT with High Intensity Flattening-Filter-Free Beams in Comparison to VMAT for Head and Neck Cancers
J. Duan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
Christopher M. Nutting et al.
LANCET ONCOLOGY (2011)
Impact of image-guided radiotherapy to reduce laryngeal edema following treatment for non-laryngeal and non-hypopharyngeal head and neck cancers
Nam P. Nguyen et al.
ORAL ONCOLOGY (2011)
Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head and neck cancer
Nam P. Nguyen et al.
ORAL ONCOLOGY (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
No Evidence of Sex-Related Survival Disparities among Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care: A Matched-Pair Analysis
Jess C. Roberts et al.
CLINICAL CANCER RESEARCH (2010)
ATYPICAL CHEST PAIN IN THE ELDERLY: PREVALENCE, POSSIBLE MECHANISMS AND PROGNOSIS
Chung-Lieh Hung et al.
INTERNATIONAL JOURNAL OF GERONTOLOGY (2010)
Effectiveness of image-guided radiotherapy for laryngeal sparing in head and neck cancer
Nam P. Nguyen et al.
ORAL ONCOLOGY (2010)
SENSORINEURAL HEARING LOSS AFTER TREATMENT OF NASOPHARYNGEAL CARCINOMA: A LONGITUDINAL ANALYSIS
S. H. Chan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
RELATIVE CONTRIBUTIONS OF RADIATION AND CISPLATIN-BASED CHEMOTHERAPY TO SENSORINEURAL HEARING LOSS IN HEAD-AND-NECK CANCER PATIENTS
Ying J. Hitchcock et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Volumetric modulated arc therapy: IMRT in a single gantry arc
Karl Otto
MEDICAL PHYSICS (2008)
Effects of anemia on the rehabilitation outcomes in elderly patients in the post-acute care setting
Maciej Witkos et al.
BLOOD (2007)
Prospective Randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients
Michael K. M. Kam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risk factors of ototoxicity after cisplatin-based chemoirradiation in patients with locally advanced head-and-neck cancer: A multivariate analysis
Charlotte L. Zuur et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Sensorineural hearing loss after radiotherapy and chemoradiotherapy: A single, blinded, randomized study
WK Low et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison
KC Soo et al.
BRITISH JOURNAL OF CANCER (2005)
Impact of dysphagia on quality of life after treatment of head-and-neck cancer
NP Nguyen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Reasons for non-standard treatment in elderly patients with advanced head and neck cancer
W Derks et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2005)
Dysphagia following chemoradiation for locally advanced head and neck cancer
NP Nguyen et al.
ANNALS OF ONCOLOGY (2004)
Combined chemotherapy and radiation therapy for head and neck malignancies - Quality of life issues
NP Nguyen et al.
CANCER (2002)
Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain
JG Canto et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
